


301 Rec'd PCT/PTO 17 DEC 1999

FORM PTO-1380 (Rev. 0-99)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 001560-377
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/446089
INTERNATIONAL APPLICATION NO. PCT/JP 99/02045	INTERNATIONAL FILING DATE April 16, 1999	PRIORITY DATE CLAIMED April 17, 1998	
TITLE OF INVENTION GENE ENCODING A PROTEIN HAVING AURONE SYNTHESIS ACTIVITY			
APPLICANT(S) FOR DO/EO/US Keiko SAKAKIBARA, Yuko FUKUI, Yoshikazu TANAKA, Takaaki KUSUMI, Masako MIZUTANI, Toru NAKAYAMA			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1). 4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern other document(s) or information included: 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input type="checkbox"/> Other items or information:			

420 Rec'd PCT/PTO 17 DEC 1999

U.S. APPLICATION NO. 09/446089		INTERNATIONAL APPLICATION NO. PCT/JP 99/02045	ATTORNEY'S DOCKET NUMBER 001580-377
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)):			
Search Report has been prepared by the EPO or JPO \$840.00 (970)			
International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00 (956)			
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00 (958)			
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00 (960)			
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00 (962)			
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 840.00	
Surcharge of \$130.00 (154) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). 20 <input type="checkbox"/> 30 <input type="checkbox"/>		\$	
Claims	Number Filed	Number Extra	Rate
Total Claims	17 -20 =	0	X\$16.00 (966)
Independent Claims	1 -3 =	0	X\$78.00 (964)
Multiple dependent claim(s) (if applicable)		+ \$260.00 (968)	\$ 0.00
TOTAL OF ABOVE CALCULATIONS =		\$ 840.00	
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).		\$	
SUBTOTAL =		\$ 840.00	
Processing fee of \$130.00 (166) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). 20 <input type="checkbox"/> 30 <input type="checkbox"/>		\$	
TOTAL NATIONAL FEE =		\$ 840.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31), per property +		\$ 40.00	
TOTAL FEES ENCLOSED =		\$ 880.00	
		Amount to be: refunded \$	
		charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>880.00</u> to cover the above fees is enclosed.			
b. <input type="checkbox"/> Please charge my Deposit Account No. <u>02-4800</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.			
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-4800</u> . A duplicate copy of this sheet is enclosed.			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO:			
Ronald L. Grudziecki BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404 Alexandria, Virginia 22313-1404			
		SIGNATURE	
		NAME	Donna M. Meuth
		REGISTRATION NUMBER	36,607

09 / 4 4 6 0 8 9

420 Rec'd PCT/PTO 17 DEC 1999

Patent

Attorney's Docket No. 001560-377**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of)
)
KEIKO SAKAKIBARA et al.) Group Art Unit: Unassigned
)
Application No.: Unassigned) Examiner: Unassigned
Corresponding to PCT/JP99/02045)
)
Filed: December 17, 1999)
)
For: GENE ENCODING A PROTEIN)
HAVING AURONE SYNTHESIS)
ACTIVITY)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-cited Application on the merits, please amend the
application as follows:

IN THE CLAIMS:

In claim 3, line 1, please delete "or 2".

In claim 4, line 1, please delete "or 2".

In claim 5, line 1, please delete "or 2".

In claim 6, please delete "any one of claims 1 through 5" and insert therefor --claim 1--.

In claim 10, please delete "any one of claims 1 through 5" and insert therefor --claim 1--.

In claim 13, line 5, please delete "or claim 11".

Patent
Attorney's Docket No. 001560-37

In claim 14, line 2, please delete "or claim 11".

In claim 15, please delete "any one of claims 1 through 5" and insert therefor --claim 1--.

In claim 16, please delete "any one of claims 1 through 5" and insert therefor --claim 1--.

REMARKS

Entry of the foregoing and early and favorable consideration of the subject application is respectfully requested.

By the present amendment, claims 3-6, 10, and 13-16 have been amended to remove multiple dependency. No new matter has been added.

In the event that there are any questions concerning the present amendment, or the application in general, the Examiner is respectfully urged to telephone the undersigned attorney so that prosecution of this application may be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Donna M. Meuth
Registration No. 36,607

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: December 17, 1999

- 1
420 Rec'd PCT/PTO 17 DEC 1999

SPECIFICATION

GENE ENCODING A PROTEIN HAVING AURONE SYNTHESIS ACTIVITY

5 Field of the Invention

The present invention relates to genes encoding proteins having activity that synthesizes aurones by using chalcones as substrates, and its utilization. More specifically, the present invention relates to genes
10 encoding polyphenoloxidases having activity that synthesizes aurones by using chalcones as substrates, and its utilization. More specifically, the present invention, for example, relates to genes encoding proteins derived from snapdragons having activity that
15 synthesizes aurones by using chalcones as substrates.

Background Art

The flower colors of orange, red, violet and blue primarily are provided by flavonoids referred to as
20 anthocyanins. Although yellow is mainly provided by compounds other than flavonoids, such as carotenoids, betalains, etc., the yellow color of some plants is provided by flavonoids. For example, compounds
25 classified as aurones are known to be present in the petals of some varieties of snapdragon, limonium, morning glory, dahlia, strawflower, Jerusalem artichoke and cosmos (Saito: BIO HORTI 1, 49-57, 1990).

Known examples of aurones include 4',6-dihydroxyaurone, 4,4',6-trihydroxyaurone, aureusidin,
30 sulfretin and bracteatin, with aureusidin and bracteatin being contained in snapdragon, aureusidin contained in limonium, aureusidin contained in morning glory, sulfretin contained in dahlia, bracteatin contained in strawflower, and sulfretin contained in Jerusalem
35 artichoke.

In addition, aurones are known to be contained in the plant of the family Compositae including the genera

Coreopsis, Helianthus, Tithonia, Zinnia and Viguiera; the family Ericaceae including the genus Vaccinium; the family Cyperaceae including the genus Cyperus; the family Leguminosae including the genera, Acacia, Pterocarpus and Soja; and the family Rubiaceae including the genus Mussaenda (The Flavonoids, edited by J.B. Harbone, 1988, Chapman & Hall, 340-342).

The synthesis pathway of anthocyanins has been extensively researched, and with respect to the biosynthesis of aurones, it has been suggested based on its structure that 4',6-dihydroxyaurone is synthesized from 2',4,4'-trihydroxychalcone, and it has been proposed that peroxidase is involved in that reaction (Rathmel and Bendall, Biochem. J. 127, 125-132, 1972). However, there are no examples of definitively measuring the biosynthesis reaction of aurones using petal extracts and so forth of plants, and there are no reports that clarify the manner in which the reaction occurs in plant petals. In addition, there are also no reports of purifying enzymes involved in aurone synthesis.

Disclosure of the Invention

Therefore, the inventors of the present invention have attempted to clarify the biosynthesis mechanism of aurones to provide a means for controlling the color of plants, and particularly their flowers.

The inventors of the present invention established an assay method for measuring the reaction by which aurones are synthesized from chalcones using a crude extract of snapdragon petals containing aurones. The aurones produced at this time are not 4',6-dihydroxyaurone considered in the prior art, but rather aureusidin, and this reaction that can now be measured has not been previously known. In addition, an enzyme (aureusidin synthase) that synthesizes aurones (aureusidin) by using chalcones as substrates from the petals of snapdragons was purified by electrophoresis to

a single band, by using the assay method. The biochemical properties of this enzyme were identified using this pure standard. In addition, the partial amino acid sequences of this enzyme were also determined. A
5 gene for this aurone synthase, which synthesizes aurones by using chalcones as substrates, was obtained from a cDNA library prepared from the petal of snapdragon, based on the partial amino acid sequences as described above.

Note that known examples of chalcones include, but
10 not restricted to tetrahydroxychalcone, pentahydroxychalcone, butein and 2',4,4'-trihydroxychalcone.

On the other hand, the resulting gene has homology in the copper binding region, which is the active center
15 of polyphenol oxidase. Therefore, it was confirmed whether tyrosinase, which is known as a kind of polyphenol oxidases, has activity to synthesize aurones from chalcones or not, and as a result, tyrosinase was also clearly shown to have activity to synthesize
20 aurones.

Thus, the present invention provides genes encoding proteins having activity to synthesize aurones by using chalcones as substrates. Moreover, it provides genes encoding polyphenol oxidase having activity to synthesize
25 aurones by using chalcones as substrates. Moreover, it provides a gene encoding a protein having activity to synthesize aurones by using chalcones as substrates, and having the amino acid sequence shown in SEQ ID NO. 2. The present invention also provides a vector containing
30 the above-mentioned gene.

Moreover, the present invention provides a host transformed by the above-mentioned vector. This host may be a microorganism, plant cells or animal cells, or it may be a plant.

35 The present invention also provides a process for production of an aurone synthase such as aureusidin synthase, characterized by culturing the above-mentioned

cells or cultivating the above-mentioned plant. The
formed enzyme can be recovered, or be made to function to
regulate the color tone in a plant. In this case,
aurones are synthesized by enzyme formed in the plant,
5 and these aurones then regulate the color of the plant
such as its petals.

Thus, the present invention also provides a method
for regulating the flower color of plants characterized
by introducing a gene for an enzyme such as aureusidin
10 synthase having activity to synthesize aurones by using
chalcones as substrates into a plant or plant cells to
express above-mentioned gene, and by synthesizing aurones
in a plant by the enzyme formed. The present invention
also provides a plant in which flower color is regulated
15 in this manner.

The present invention also provides a method of
synthesizing aurones characterized by allowing the above-
mentioned enzyme protein to act on chalcones serving as
the substrate pigment.

20 The present invention also provides an enzyme
protein encoded by the above-mentioned gene.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the structural formulas of aurones and
25 chalcones.

Fig. 2 shows the biosynthesis pathway of aurones.

Fig. 3 shows the results of Northern analysis in
each organ of yellow snapdragon using SYP8-17.

Fig. 4 shows the results of Northern analysis at
30 each stage of development of the petals of yellow
snapdragon using SYP8-17.

Petal stage 1: Bud petal length up to 1 cm
Petal stage 2: Bud petal length 1 to 1.5 cm
Petal stage 3: Bud petal length 1.5 to 2.0 cm
35 Petal stage 4: Bud petal length 2.0 to 2.5 cm
Petal stage 5: Bud petal length 2.5 to 3.0 cm
Petal stage 6: Blossomed petal 3.0 cm or more

Fig. 5 shows the results of Northern analysis in yellow, pink and white snapdragon petals using SYP8-17.

Fig. 6 is a graph showing an inhibition mode of aurone synthase activity by adding antibody against
5 aurone synthase SYP-8 (anti-SYP-8) and other reference antibodies (anti-band A and anti- β -galactosidase).

Fig. 7 shows SYP8 protein remaining in supernatant after addition of anti-SYP8-IgG-Sepharose 4B.

10 EMBODIMENT FOR CARRYING OUT THE INVENTION

To begin with, aureusidin synthase is purified by various chromatography methods from the petals of yellow snapdragon. Next, partial amino acid sequences of
15 aureusidin synthase are analyzed in accordance with a conventional method to prepare synthetic oligonucleotides encoding these amino acid sequences.

On the other hand, Poly A+RNA is prepared from the same snapdragon petals, and cDNA library is prepared in accordance with a conventional method.

20 PCR is carried out using the above-mentioned synthetic nucleotides using cDNA of yellow snapdragon petals as a template to acquire a DNA fragment specific to aureusidin synthase. This DNA fragment is subcloned in a vector to prepare a plasmid.

25 The above-mentioned cDNA library is screened using an inserted DNA contained in the above-mentioned plasmid to obtain a clone. The plasmid derived from this clone is then isolated followed by determination of the nucleotide sequence.

30 The protein having the enzyme activity has a region essential for an enzyme activity, and a region not essential for enzyme activity. It is known that enzyme activity is maintained even if the non-essential region is modified by removal (deletion) or addition of one or
35 more amino acids and/or substitution by other amino acids. Thus, the present invention includes not only a protein having the amino acid sequence shown in SEQ ID

NO. 2, but also proteins having an amino acid sequence modified by removal, deletion or addition of one or more amino acids and/or one or more substitutions by other amino acids in the amino acid sequence shown in SEQ ID
5 NO. 2 while maintaining the activity to synthesize aurones by using chalcones as substrates, as well as genes encoding the proteins.

Moreover, cases are known in which a protein having identical enzyme activity may have a different amino acid
10 sequence due to an allelic variation. Moreover, it is also known that enzymes having identical or equivalent enzyme activity are distributed over numerous species, and that these enzymes have a high degree of homology of their amino acid sequences. Genes encoding these
15 proteins can be selected by hybridization with a gene of the present invention. Thus, the present invention also includes a gene that hybridizes with nucleic acid having the nucleotide sequence shown in SEQ ID NO. 1 under a stringent condition and that encoding a protein having
20 the activity to synthesize aurones by using chalcones as substrates, and a protein encoded by the gene.

The gene that hybridizes with nucleic acid having the nucleotide sequence described in SEQ ID NO. 1 and that encoding a protein having enzyme activity to
25 synthesize aurones by using chalcones as substrates may be an artificially modified form or naturally-occurring form of a gene that encodes the amino acid sequence described in SEQ ID NO. 2. Examples of naturally-occurring genes include cDNA or genomic DNA obtained from
30 plants having aurone synthase such as snapdragon, limonium, morning glory, dahlia, strawflower and Jerusalem artichoke. The stringency for hybridization is, for example, 5 x SSC at 50°C, preferably 2 x SSC at 50°C, and more preferably 0.2 x SSC at 50°C.

35 It is well known that there are many cases in which protein, having an amino acid sequence with a high degree of identity relative to a native amino acid

sequence of a protein having enzyme activity, has enzyme activity that is similar to that of a native protein. Thus, the present invention also includes proteins having activity to synthesize aurones by using chalcones as
5 substrates and having an amino acid sequence having amino acid sequence identity of 55% or more, preferably 60% or more, preferably 70% or more, more preferably 80% or more and particularly preferably 90% or more relative to the amino acid sequence shown in Sequence ID No. 2, and a
10 gene encoding that protein.

It is also known that enzymes having equivalent enzyme activity may have common epitopes in many cases. Thus, the present invention also includes the above-mentioned various proteins having aurone synthesis
15 activity, and particularly proteins having activity that synthesizes aurones by using chalcones as substrates, which also specifically bind with an antibody against the protein having the amino acid sequence shown in SEQ ID NO. 2, and a gene encoding that protein.

In the present invention, a gene that encodes protein having the amino acid sequence shown in SEQ ID NO. 2 can be obtained from snapdragon as cDNA or genomic DNA. A method for cDNA cloning is specifically described in Examples 8 through 10. In order to obtain a genomic
20 DNA, a genomic DNA library is prepared from snapdragon in accordance with a conventional method, and this is then screened in accordance with a conventional method by cDNA or its fragment.

In the present invention, a gene that encodes a protein having a modified amino acid sequence relative to the amino acid sequence in SEQ ID NO. 2 can be prepared by modifying the nucleotide sequence of DNA such as cDNA that encodes protein having the amino acid sequence shown in SEQ ID NO. 2 in accordance with a conventional method
30 to manipulate the gene by site-directed mutagenesis, PCR and so forth.

Naturally-occurring genes, that hybridize with

nucleic acid having the nucleotide sequence described in SEQ ID NO. 1 and that encodes an enzyme having activity to synthesize aurones by using chalcones as substrates, are obtained by preparing a cDNA library or genomic DNA library from a plant which has ability to produce a protein having aurone synthase activity in accordance with a conventional method, and then screening the library by using, for example, cDNA or its fragment having the nucleotide sequence shown in SEQ ID NO. 1 as a probe. The above-mentioned conditions can be used for the hybridization at this time.

In addition, the aurone synthase obtained from snapdragon is a kind of polyphenol oxidase, therefore the inventors of the present invention, considering that other polyphenol oxidases also have activity to synthesize aurones from chalcones, examined whether an enzyme sold commercially as tyrosinase, a polyphenol oxidase derived from Neurospora, has aurone synthesis activity or not. As a result, the tyrosinase was determined to have aurone synthesis activity. Consequently, enzymes having polyphenol oxidase activity clearly have activity to synthesize aurones by using chalcones as substrates.

Although the physiological role of enzymes having polyphenol oxidase activity is not yet clear, they are primarily classified into three types which are catechol oxidase (enzyme no. 1.10.3.1), laccase (enzyme no. 1.10.3.2.) and tyrosinase (enzyme no. 1.14.18.1), and are classified with different enzyme numbers according their substrate specificity. They are copper enzymes in which copper is present in the enzyme reaction center, and high dimensional structures of proteins, etc. are thought to be a cause of substrate specificity.

In this manner, since a conserved region corresponding to the copper-binding region is present in polyphenol oxidase, polyphenol oxidase gene can be obtained according to an established method such as PCR

with a primer based on the amino acid sequence of this region (Plant Physiol., Vol. 107, pp. 1083-1089, 1995; Plant Physiol., Vol 109, pp. 525-531, 1995), and a gene encoding a protein having activity to synthesize aurones
5 can be obtained from the gene obtained as described above.

The present invention also provides a process for production of the above-mentioned proteins having activity to synthesize aurones by using chalcones as
10 substrates. This method is characterized by introducing a vector containing a DNA encoding the above-mentioned protein into a host, culturing or growing said host, and collecting the above-mentioned protein as desired. The host may be host cells or plants or other organisms.
15 Examples of host cells include procaryotic cells and particularly bacterial cells such as those of Escherichia coli, and the genus Bacillus including the species Bacillus subtilis and Bacillus brevis, and lower eucaryotes, including fungi such as yeasts like the genus
20 Saccharomyces such as the species Saccharomyces cerevisiae, or molds like the genus Aspergillus such as the species Aspergillus oryzae and Aspergillus niger.

Moreover, examples of higher eucaryotic cell hosts include insect cells such as silkworm cells, animal cells
25 such as CHO cells, and human cultured cells such as HeLa cells.

The gene described in the present invention can also be expressed in organisms such as animals and plants. A detailed description of expression in plants is provided
30 below.

A vector, and particularly an expression vector, containing DNA of the present invention contains an expression control region, and this expression control region is dependent on the host cells. For example, trc
35 promoter, tac promoter, lac promoter or T7 promoter can be used for the promoter of a bacterial expression vectors. Examples of promoters of a yeast expression

vector that can be used include promoters of glycolytic enzyme genes such as glycerolaldehyde-3-phosphate dehydrogenase promoter and galactokinase promoter. In addition, virus promoters can be used as a promoter of animal cell expression vectors.

Conventional means used to isolate and purify proteins, such as liquid chromatography and affinity chromatography, can be used to recover a protein having an activity to synthesize aurones from a culture by using chalcones as substrates. Affinity chromatography can be performed using the specific binding with antibody, for example antiserum or monoclonal antibody, against protein having aurone synthase activity of the present invention.

Antiserum (polyclonal antibody) to protein having aurone synthase activity described in the present invention can be produced by immunizing an animal such as a rabbit with protein described in the present invention, such as the protein obtained in Example 4, together with adjuvant, and obtaining serum from the animal. Monoclonal antibody can be produced by immunizing an animal such as a mouse against, for example, a protein described in the present invention in accordance with a conventional method, and fusing the B lymphocytes, such as spleen cells, obtained from a mouse, with mouse myeloma cells to obtain a hybridoma, followed by culturing that hybridoma.

Based on the current level of technology, if the cDNA can be put under the control of a constitutive or inducible promoter, and introduced into a plant such as petunia, rose, carnation, chrysanthemum, torenia, verbenas, gerbera, tobacco, strawberry, Jerusalem artichoke, gentian, gladiolus or tulip, using Agrobacterium, a particle gun or electroporation, the aurone synthase gene can be expressed in a petal and so forth.

It is predicted that aurones are synthesized in petals where aurone synthase is expressed, which cause

the yellow color of the petals. Plants obtained in this manner are able to provide new colors of flowers that do not exist for conventional varieties. In addition, some of plant species having yellow color contain carotenoids (chrysanthemums and roses) or betalain (cactus), but the tone of these yellow colors are different from those by aurones. Therefore, the present invention is also useful in enlarging the spectrum of color tones of plant species already having yellow color.

Some snapdragons having yellow flowers are deficient in chalcone isomerase activity and have aurone synthase. Since chalcone isomerase acts competitively with aurone synthase, naringenin is formed from tetrahydroxychalcone in the presence of chalcone isomerase, and this ultimately becomes anthocyanin and flavone. Thus, when producing aurones by expressing aurone synthase gene in plants, it is preferable that the plant be deficient in chalcone isomerase.

In general, it is possible to artificially suppress the activity of plant genes, and there are numerous known examples of suppressing genes involved in flavonoid synthesis in particular. An antisense method and a cosuppression method are used to artificially suppress gene expression, and genes involved in flavonoid synthesis have been found to be able to be suppressed by either of these methods (van der Krol, et al., Nature (1988) 333, 866-869; Napoli, et al., Plant Cell (1990) 2, 279-289). It is also possible to suppress expression of chalcone isomerase gene in the same way.

Chalcone isomerase gene has already been obtained from plant species, such as petunia, alfalfa, snapdragon, apple, kidney bean and grape (Holton, et al., Plant Cell (1995) 7, 1071-1083). Comparison of the amino acid sequences of these chalcone isomerases reveals that the sequence is well conserved among species. There are many examples that genes involved in flavonoid synthesis can be easily cloned by using a corresponding gene derived

from another plant as a probe. Alternatively, cloning can also be performed by PCR using a conserved region of known genes or amino acid sequences compared with each other. Thus, chalcone isomerase gene can be easily
5 obtained from any plant species (Guttererson, Hort. Sci., Vol. 30, pp. 964-966, 1995).

In addition, similar effects can be expected by suppressing gene expression of flavanone-3-hydroxidase or dihydroflavonol-4-reductase. Since these enzyme genes
10 have also been obtained from numerous plant species (Gong, et al., Plant Mol. Biol., 35, pp. 915-927, 1997), they can be obtained from any plant species by using a method similar to the case of chalcone isomerase.

Thus, in order to breed a certain plant species
15 having yellow flowers provided by aurones, the aurone synthase gene should be expressed in the petals. Preferably, the aurone synthase gene should be expressed while suppressing the expression of chalcone isomerase gene. In this case, the promoters used to regulate
20 expression of these genes may be constitutional promoters or petal-specific promoters. More preferably, these techniques allow to obtain flowers with stable yellow color in combination with introduction of a glycosyltransferase gene that adds a sugar to the aurone.
25 These techniques are possible with the current level of technology.

Furthermore, in dahlia and snapdragon, flower color is known to become brown when both anthocyanins and aurones are present. It is possible to breed brown
30 flowers by introducing aurone synthase into a plant that produces anthocyanins in its flowers. Such flowers are also industrially important as a new color of flowers.

Examples

35 The following provides a detailed description of the invention through its examples.

Example 1. Preparation of Tetrahydroxychalcone

20 ml of 50% (v/w) potassium hydroxide were added to 4 g of naringenin and completely dissolved. After holding this solution at 100°C for 90 seconds, the solution was immediately diluted and cooled with 300 ml of ice water to stop the reaction. Next, 6 N hydrochloric acid was added to this solution in a draft chamber to lower the pH to 3 or lower and form a precipitate. The resulting yellow precipitate was filtered out of solution and dissolved in a minimum amount of ethanol, followed by the addition of 400 ml of cold water a little at a time while cooling over ice. After allowing to stand overnight, the precipitate obtained by centrifuging at 8000 rpm for 30 minutes was resuspended in water and freeze-dried. The weight of crude tetrahydroxychalcone (THC) after freeze-drying was 2.7 g.

The crude THC was dissolved in a minimum amount of methanol, and the THC was purified by reverse phase high-performance liquid chromatography. The THC was developed using the Shimakyuu YMC D-ODS-5 S-5 120A (2.0 cm x 25 cm) at a flow rate of 4.5 ml/min in an aqueous solution of 40% (v/v) acetonitrile and 0.03% (v/v) trifluoroacetic acid. THC was eluted at about 25 minutes, while naringenin was eluted at about 29 minutes. The THC fractions were collected and freeze-dried. Chromatography was repeated once under the same conditions to obtain purified THC.

Example 2. Preparation of Aureusidin

290 g of the petals of snapdragon cultivar Butterfly Yellow were crushed in liquid nitrogen and soaked overnight in 2 liters of 50% acetonitrile containing 0.1% TFA. After filtering through diatomaceous earth and concentrating the filtrate under reduced pressure, the concentrate was purified with HP-20. The yellow pigment fraction was concentrated and applied to a separation HPLC. Using water as solution A and 0.1% TFA in 50% acetonitrile as solution B, chromatography was performed

using the Shimakyuu YMC D-ODS-5 S-5 120A (2.0 cm x 25 cm) under gradient condition of 120 minutes at a linear concentration gradient from 20% B to 60% B. As a result, bracteatin-6-glucoside was eluted at 40 minutes, aureusidin-6-glucoside was eluted at 53 minutes, and tetrahydroxychalcone-4-glucoside was eluted at 100 minutes. The resulting aureusidin-6-glucoside was hydrolyzed with β -glucosidase to obtain aureusidin.

Example 3. Measurement Method of Aurone Synthase

Activity

The reaction was started by adding 5 μ l of THC, having an absorbance of 462 at 366 nm in ethanol, to 50 μ l of 1 M sodium acetate buffer (pH 5.0) and 350 μ l of crude enzyme solution diluted with water. After allowing to react for 1 hour at 30°C, and adding 100 μ l of an aqueous solution of 90% (v/v) acetonitrile containing 1% (v/v) TFA to stop the reaction, activity was measured by HPLC. The crude enzyme solution in each purification step described later in Example 4 was measured.

The YMC J'Sphere ODS M80 column (4.6 x 150 mm) was used and the flow rate was set at 0.7 ml/min. Using a 0.1% aqueous solution of TFA as solvent A, and a 90% aqueous solution of acetonitrile containing 0.1% TFA as solvent B, a sample was injected into the column, after which the ratio of A:B was held at 7:3 for first 3 minutes, and then changed to 6:4 by a linear concentration gradient for next 10 minutes. This concentration was maintained for 5 minutes. After changing the ratio of A:B to 7:3 for next one minute, this concentration was maintained for 5 minutes. The substrate THC was eluted at about 20.9 minutes under these conditions. A compound eluted at about 8.8 minutes was detected as a reaction product. This compound was aureusidin as described later.

Aureusidin was determined to be formed from THC by this reaction.

Example 4. Purification of Aurone Synthase

1) Enzyme Purification

Enzyme purification was carried out using as a starting material 32,175 g of snapdragon buds from which
5 white petals were peering out from between calyx and flowers that had started to be colored yellow. 2400 ml of chilled buffer A (0.01 M sodium acetate, pH 5.0) and 120 g of polyvinylpyrrolidone (PVPP) were added per approximately 600 g of flowers and then crushed for 1 to
10 1.5 minutes with a whirling blender.

Extracts from the crushed flowers were centrifuged at 8000 rpm and 4°C for 15 minutes, and ammonium sulfate was dissolved to 60% of saturation in the resulting supernatant. After stirring to dissolve,
15 the solution was allowed to stand. The precipitate collected by centrifuging at 8000 rpm and 4°C for 15 minutes was suspended in a minimum amount of buffer A and dialyzed against buffer A. The dialysate was centrifuged at 8000 rpm and 4°C for 15 minutes, and the resulting
20 supernatant was used as ammonium sulfate fraction concentrate. The ammonium sulfate fraction concentrate was stored frozen at -20°C until SP-Sephadex C50 chromatography.

2) SP-Sephadex C50 Chromatography

The resulting ammonium sulfate fraction
25 concentrate was subjected to the following procedure three times. The electrical conductivity of the ammonium sulfate fraction concentrate was measured after dialysis, and the concentrate was diluted with cold deionized water
30 as necessary until the electrical conductivity became 0.8 to 1 mS at 4°C. The ammonium sulfate fraction concentrate was applied onto an SP-Sephadex C50 column (6 cm x 25.5 cm; approx. 0.7 liters) which had been equilibrated thoroughly with buffer B (buffer A
35 containing several μ M THC). After the application, the column was thoroughly washed with buffer B. Elution was performed in 23 ml fractions while washing the column by

applying a linear concentration gradient between buffer B (2.0 liters) and buffer B containing 0.6 M NaCl (2.0 liters). The active fractions (approx. 1200 ml) were collected, sterilized by filtration, and stored at 4°C until ConA Sepharose chromatography.

3) ConA Sepharose Chromatography

ConA Sepharose chromatography was performed in twice for fraction A (containing 374,000 U in 1100 ml) and fraction B (containing 831,000 U in 2900 ml). MnCl_2 and CaCl_2 were dissolved in the fraction A to 1 mM each and applied onto a ConA Sepharose column (2 cm x 12 cm; approx. 40 ml) which had been equilibrated with buffer C (buffer B containing 1 mM MnCl_2 , 1 mM CaCl_2 and 0.5 M NaCl). After the application, the column was washed with approximately 0.3 liters of buffer C. The flow-through fraction and washing fraction (300 ml) contained 50,000 U each of activity respectively before application (13% each of the original activity).

After washing, elution was performed in 4 ml fractions while washing the column by applying a linear concentration gradient between buffer C (250 ml) and buffer C containing 0.2 M methyl- α -D-glucoside and 0.2 M methyl- α -D-mannopyranoside (250 ml) so as to collect active fractions (total 78 ml). The active fraction was thoroughly dialyzed against buffer D (5 mM potassium phosphate buffer (pH 5.0), 0.3 mM CaCl_2 and 3 to 6 μM THC). The washing fraction was combined with the remaining fraction B, and the second round of chromatography was carried out.

MnCl_2 and CaCl_2 were each dissolved to 1 mM in the remaining active fraction B, and applied onto a ConA Sepharose column (3.6 cm x 12 cm; approx. 120 ml) which had been equilibrated with buffer C. After the application, the column was washed with approximately 0.3 liters of buffer C. The flow-through fraction and washing fraction (300 ml) contained little activity.

After washing, elution was performed in 8 ml fractions while washing the column by applying a linear concentration gradient between buffer C (350 ml) and buffer C containing 0.2 M methyl- α -D-glucoside and 0.2 M methyl- α -D-mannopyranoside (350 ml) so as to collect active fractions (total 150 ml). After thoroughly dialyzing the active fraction against buffer D, the dialyzate was combined with the previous sample to obtain a active fraction (total 250 ml).

10 4) Gigapite Chromatography

Dialysate (250 ml) was applied onto a Gigapite column (Biochemical Industries, 2 cm x 16 cm, 50 ml open column) which had been equilibrated with buffer D. After the application of the sample, the column was washed with buffer D (250 ml). Elution was performed in 4 ml fractions while washing the column by applying a linear concentration gradient between buffer D (200 ml) and 0.5 M potassium phosphate buffer (pH 5.0) (200 ml) so as to collect active fractions (total 120 ml).

20 5) HiLoad 16/60 Superdex 75 pg FPLC

{3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate} (CHAPS) was dissolved to a final concentration of 0.1% in the active fraction, followed by ultrafiltration using an Amicon PM10 film to concentrate to 18 ml. The following procedure was performed 6 times on the concentrated active fraction.

A chilled HiLoad 16/60 Superdex 75 pg column was equilibrated with buffer B containing 0.07% CHAPS and 0.15 M NaCl, eluted at a flow rate of 0.5 ml/min to obtain 2 ml fractions using an FPLC system. Active fractions were collected (total 63 ml).

30 6) SP-Sepharose FF FPLC

The resulting active fraction was thoroughly dialyzed at 4°C against buffer E (buffer B containing 0.07% CHAPS). The following chromatography procedure was performed twice using an FPLC system. A chilled SP-

Sepharose FF column (1 x 16 cm) was equilibrated with buffer E. After applying the sample onto the column, buffer E was used as solution A and buffer E containing 0.7 M NaCl was used as solution B. The column was washed for first 30 minutes with 95% solution A and 5% solution B, a linear concentration gradient to 55% solution A and 45% solution B was then applied for next 120 minutes, followed by elution for next 10 minutes under the same conditions. Elution was performed in 1.0 ml fractions at a flow rate of 0.5 ml/min. Active fractions (total 27.8 ml) were collected and stored at 4°C after sterilizing by filtration.

7) Gigapite Column Chromatography

22 ml of the active fraction was further purified by Gigapite (1 x 14 cm) FPLC. 22 ml of sample was dialyzed overnight at 4°C against 0.005 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS, FPLC was performed under the following conditions, and the correlation between activity and protein band behavior was observed. FPLC was performed while chilling the column and buffer using 0.005 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS and 0.3 mM CaCl₂ as solution A, and 0.5 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS as solution B.

After washing the column for 30 minutes with 100% solution A at a flow rate of 0.5 ml/min, a linear concentration gradient to 95% solution A and 5% solution B was applied for next 6 seconds, and then to 20% solution A and 80% solution B for next 149 minutes 54 seconds, followed by eluting under the same conditions for next 155 minutes in 1.0 ml fractions.

Those fractions were collected that contained 40 kDa protein which demonstrated the best correlation with activity behavior based on chromatography and activity measurement results, and were used in primary structure analysis.

Example 5. Activity Measurement for Three Types
Column Chromatography and SDS-PAGE

1) Superdex 200 Smart System

Fractionation was performed with a Superdex 200
5 Smart System using 50 µl of sample. The following
procedure was performed at 4°C using 0.01 M sodium
acetate (pH 5.0) containing 0.07% CHAPS and 0.15 M NaCl
as a solvent. Gel filtration chromatography was
performed by fractioning in 40.0 µl aliquots at a flow
10 rate of 40.0 µl/min. Activity measurement and SDS-PAGE
was performed for the sample. Enzyme activity was eluted
in the vicinity of a molecular weight of 43 kDa, and
among those proteins contained in the sample, the
behavior of the 40 kDa protein correlated most closely
15 with activity behavior.

2) Alkyl-Sepharose HR5/5 FPLC

250 µl of sample was dialyzed overnight at 4°C
against 0.01 M sodium acetate (pH 5.0), and ammonium
sulfate was dissolved to a final concentration of 2 M.
20 Alkyl-Sepharose HR5/5 FPLC was performed at room
temperature. Using 0.01 M sodium acetate (pH 5.0)
containing 2 M (NH₄)₂SO₄ as solution A, and 0.01 M sodium
acetate (pH 5.0) as solution B, the column was washed
with 100% solution A for first 10 minutes, a linear
25 concentration gradient to 100% solution B was applied for
next 50 minutes, and elution was performed for next 5
minutes under the same condition in 0.5 ml fractions.

400 µl of each fraction was concentrated to 40
µl with Ultra-Free C3GC (molecular weight fractionated:
30 10,000, Millipore), and 10 µl of the concentrate was
analyzed by SDS-PAGE and measured activity. Among the
proteins contained in the sample, the best correlation
was observed between activity behavior and the behavior
of the 40 kDa protein.

35 3) Gigapite HR5/5 FPLC

300 µl of sample was dialyzed overnight at 4°C against 0.005 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS. Gigapite HR5/5 FLPC was performed at room temperature under the following conditions.

Using 0.005 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS and 0.3 mM CaCl₂ as solution A, and 0.5 M potassium phosphate buffer (pH 5.0) containing 0.07% CHAPS as solution B, the column was washed with 100% solution A for first 5 minutes, and a linear concentration gradient to 80% solution A and 20% solution B was applied for next 6 seconds and then to 20% solution A and 80% solution B for next 44 minutes 54 seconds, after which 0.5 ml fractions were eluted. Activity measurement and SDS-PAGE electrophoresis were then performed. Among the proteins contained in the sample, the best correlation was observed between the behavior of the 40 kDa protein and activity behavior.

As a result of conducting column chromatography with the Superdex 200 Smart System, Alkyl-Sepharose FPLC and Gigapite FPLC, a close correlation was demonstrated between the behavior of the approximately 40 kDa protein band and activity behavior.

Example 6. Characteristics of Aurone Synthase

It was confirmed that purified aurone synthase converts both THC and pentahydroxychalcone to aureusidin. The resulting product was confirmed to be aureusidin by HPLC analysis.

The molecular weight of this enzyme was determined to be 40 kDa with SDS polyaklylamide gel electrophoresis, and 43 kDa with gel electrophoresis using Superdex 200. This data revealed that aurone synthase is a monomer. Enzyme activity was inhibited by 90% or more in the presence of 1 mM monovalent copper ion, bivalent copper ion, bivalent iron ion and trivalent iron ion. In addition, binding to ConA Sepharose suggested the possibility that the enzyme contains sugar. In addition,

activity increased somewhat when hydrogen peroxide was added.

A product expected to be aureusidin was formed when the enzyme reacted with THC as substrate, and its structure was determined by collecting a large amount of this product. 20 ml of 1 M sodium acetate buffer (pH 5.0) containing 10 mM hydrogen peroxide, 20 ml of enzyme solution, 58 ml of water and 10 mg (0.5 ml) of THC were mixed and held for 3.5 hours at 30°C. After reacting, the reaction mixture was adsorbed onto Sep-Pak C18 and eluted with methanol. After concentrating with an evaporator, it was purified with separation HPLC, using a YMC D-ODS-5 S-5 120A (2.5 x 25 cm) column. Elution was performed at a flow rate of 4.5 ml/min using an aqueous solution of 40% acetonitrile containing 0.03% TFA. The peak that eluted at approximately 17 minutes was collected and dried to obtain approximately 4.9 mg of product. Determination of the structure of the compound by ¹H-NMR and mass spectrometry revealed it to be aureusidin.

Example 7. Determination of Amino Acid Sequences of Aurone Synthase

Approximately 1 nmol of the resulting aurone synthase, to which SDS had been added to a final concentration of 2%, was subjected to a preparative electrophoresis (Biophoresis, Atoh) under non-reducing conditions so as to recover a polypeptide having a molecular weight of 41,000. When this polypeptide was separated with reverse-phase HPLC using a C4 column (Develosil 300C4-HG-5), a single peak was detected, confirming that the recovered aurone synthase is pure.

This polypeptide was digested by lysylendopeptidase AP1. The buffer for the reaction was 40 mM Tris-HCl (pH 9.5) containing 0.01% Tween 20 and 2 M urea. The digestion product was purified with reverse-phase HPLC using a Bakerbond ODS (4.6 mm x 25 cm) column. Namely, an aqueous solution of 0.05% trifluoroacetic acid was

used as solution A, and 80% acetonitrile containing 0.05% trifluoroacetic acid was used as solution B, and a linear concentration gradient to 90% solution A and 10% solution B was applied for first 5 minutes, and then to 100% solution B for next 80 minutes to separate the peptides.

The sequences of the purified peptides were determined with a peptide sequencer using a vapor phase method. The determined sequences are shown below.

P5: (K)KLGIVYQDVEIP (SEQ ID No. 3)

10 P8: (K)IVYRQMVSSAK (SEQ ID No. 4)

P11: (K)TPQLFFGRPYRRGDQEF (SEQ ID No. 5)

P4-5: (K)IIDFELXPSTTMRVRRAAHLVDDAYIXK (SEQ ID No. 6)

Example 8. Construction of cDNA Library of Snapdragon Petals

15 A cDNA library from snapdragon petals was constructed according to the method described below. RNA was obtained from 5 g of fresh petals collected immediately before blooming from yellow snapdragons by using guanidine thiocyanate/cesium chloride as described in detail in Methods in Molecular Biology, Vol. 2 (Humana Press Inc., 1984) of R. McGookin, et al., followed by purification of PolyA+RNA using Oligodex dT30 (Roche Japan). A cDNA library was then prepared with this 20 PolyA+RNA and λ ZAPII (Stratagene) as a vector, by using a cDNA synthesis kit and Uni-XR vector kit (Stratagene), as recommended by Stratagene. The resulting library was composed of 1.6×10^5 plaque-forming units (pfu). 25

Example 9. Acquisition of Gene Expressed in Yellow Snapdragons by Subtraction

30 Subtraction is one of a method for acquiring a gene specifically expressed in a certain tissue at a certain time, and here was carried out using the PCR-Select™ cDNA Subtraction Kit (Clontech) as recommended. cDNA 35 derived from yellow snapdragon petals was used as a tester, while mRNA derived from pink snapdragon petals

5 Among these, the amino acid sequence expected to be
 encoded by a gene named SYP8 is shown in Sequence ID No.
 7.

Within this amino acid sequence, the sequence consisting of 25 amino acids from the N-terminal and the sequence consisting of 4 amino acids from the C-terminal coincided with sequences P5, P8 and P11 obtained in Example 7. Namely, this gene fragment was found to encode aurone synthase.

The previously described snapdragon cDNA library was
20 screened by using the DNA fragment SYP8. Screening of
the library was performed by using a non-radioactive
system DNA detection kit (Boehringer). As a result of
screening approximately 200,000 plaques, a large number
of positive signals were obtained. 20 of these plaques
25 were randomly selected, pure plaques were isolated by
secondary screening, and the nucleotide sequence of the
longest clone among these, SYP8-17, was determined.

The nucleotide sequence was determined with a synthesized oligonucleotide primer by using a DNA Sequencer Model 373A (ABI). This nucleotide sequence and its deduced amino acid sequence are shown in SEQ ID No. 1. When a database search was performed for this amino acid sequence, this gene demonstrated low homology with polyphenoloxidase gene (GenBank Association No. L29451, D45385, Z11702), and it was found to be a novel gene. Furthermore, the main region having homology with

polyphenoloxidase was a copper-binding region which is the active center of polyphenoloxidase.

Example 11. Expression Manner of Aurone Synthase

Gene

5 Organs and petals of yellow snapdragon at each stage of developments were used for Northern analysis by using SYP8-17 as a probe. In addition, Northern analysis was also performed by using the petals of yellow, pink and white snapdragons. The method was according to Molecular Cloning (Sambrook, et al., Cold Spring Harbour Laboratory Press, 1989). The results are shown in Figs. 3, 4 and 5. Aurone synthase gene was specially expressed in petals, and moreover the expression in petals occurs parallel to biosynthesis of aurones. In addition, in the pink and white petals of snapdragons in which the accumulation of mRNA of aurone synthase gene was either low or not observed at all, aurone synthesis activity was extremely weak or not detected as compared with that in the yellow petals of snapdragons. These results suggest that the resulting gene is involved in aurone synthesis.

Example 12. Preparation of Verbena cDNA Library

mRNA was purified in the manner previously described from 5 g of fresh flower buds of Verbena variety Hanatemari Violet (Suntory), followed by preparation of a cDNA library, as described in Example 8. A resulting library was composed of 0.8×10^6 plaque-forming units (pfu).

Example 13. Cloning of Verbena Chalcone Isomerase

cDNA

30 The following primers were synthesized based on the amino acid sequences, Phe-Val/Ile-Lys-Phe-Thr-Ala-Ile (SEQ ID NO.8), Lys-Trp-Lys-Gly-Lys-Thr/Pro (SEQ ID NO.9) and a reverse sequence of a amino acid sequence, His-Ala-Val-Cys-Asn-Glu (SEQ ID NO.10), these amino acid sequences are well conserved sequences compared with the known amino acid sequences of chalcone isomerase derived from higher plants.

CHI-F1: 5'-TT(T,C) (A,G)TN AA(A,G) TT(T,C) ACN GCN
AT-3' (SEQ ID NO. 11)

CHI-F2: 5'-AA(A,G) TGG AA(A,G) GGN AA(A,G) (A,C)C-3'
(SEQ ID NO. 12)

5 CHI-R2: 5'-(A,G)TG NGC NAC (A,G)CA (A,G)TT (T,C)TC-
3' (SEQ ID NO. 13)

Using a combination of primers of previously
synthesized CHI-F1 and CHI-R2, or CHI-F2 and CHI-R2,
after reacting for 2 minutes at 96°C, the reaction was
10 repeated 30 times for 1 minute at 96°C, 1.5 minutes at
42°C and 3 minutes at 72°C, and finally reacted for 7
minutes at 72°C. When PCR was performed again under the
same conditions using the resulting PCR product as a
template, an approximately 200 bp PCR product was
15 amplified for the combination of CHI-F1 and CHI-R2
primers, while approximately 800, 600, 400 and 150 bp PCR
products were amplified with the combination of CHI-F2
and CHI-R2 primers.

The resulting PCR products were subcloned to PCRII™
20 vector using a TA cloning kit (Invitrogen). The
nucleotide sequences of the subcloned DNA fragments were
determined by using the DNA Sequencer Model 373A (ABI).
The PCR products obtained with each combination of
primers CHI-F1 and CHI-R2, or primers CHI-F2 and CHI-R2,
25 each had a common sequence with different lengths of 222
bp and 159 bp. The deduced amino acid sequences of these
products exhibited a high degree of homology with
chalcone isomerase derived from other higher plants.

PCR was performed by using CHI-F1 and CHI-R2 primers
30 and an approximately 230 bp fragment obtained by
digesting PCRII™ vector containing 222 bp Hanatemari
chalcone isomerase as a template. After reacting for 2
minutes at 95°C by PCR using the amplified PCR product of
approximately 230 bp as a template, the reaction was
35 repeated 25 times for 1 minute at 95°C, for 1 minute at
42°C and for 4 minutes at 72°C, and finally reacting for

7 minutes at 72°C, after which it was labeled with digoxigenin and used as a probe for screening. Screening from the Hanatemari cDNA library was carried out by the recommended method with a non-radioactive system DNA detection kit (Boehringer).

The chalcone isomerase genes of other plants can also be obtained by using a similar method.

Example 14. Preparation of SYP8 Antigen

SYP8 gene described in Example 9 was expressed in E. coli using the QIA Expressionist Kit (QIAGEN) and an expression product was purified. Since the molecular weight of the purified preparation of aurone synthase is 40 to 43 kDa, the peptides of the N-terminal and C-terminal were predicted to be truncated in the mature protein.

Therefore, QESYP8-5' and QESYP8-3' primers were synthesized so as to express the region from the 61st glycine residue to the 416th lysine residue of the amino acid sequence shown in SEQ ID NO. 2.

QESYP8-5': 5'-AA GAA TCC GGC CCT ATC GCC-3' (SEQ ID NO. 14)

QESYP8-3': 5'-GGG TTC GAA GAA TTC ATC TCT G-3' (SEQ ID NO. 15)

A BamHI site was introduced into the QESYP8-5' primer, and a HindIII site was introduced into the QESYP8-3' primer. A PCR reaction was carried out using a reaction mixture of a total of 100 µl comprising 30 pmol each of the synthesized QESYP8-5' and QESYP8-3' primers, 1 ng of SYP8-17 gene, 1 x cloned pfu DNA polymerase buffer (Stratagene), 200 µM dNTPs and 5 units of cloned pfu DNA polymerase (Stratagene). After holding at 94°C for 45 seconds, the reaction was carried out for 25 cycles consisting of 45 seconds at 94°C, 45 seconds at 50°C and 4 minutes at 72°C, after which the reaction was finally held at 72°C for 10 minutes. The resulting PCR product was subcloned to pCR2.1·TOPO™ vector by using a

TA cloning kit (Invitrogen) to obtain plasmid pCR·QESYP8. pCR·QESYP8 was treated with BamHI and HindIII, and a resulting DNA fragment of approximately 1 kb was ligated to a pQE30 vector (QIAGEN) which had been similarly
5 treated with BamHI and HindIII so as to construct plasmid pQESYP8. pQESYP8 was transformed into E. coli M15 [pRep4]. Expression of SYP8 protein in E. coli and its purification were performed according to the method recommended by the manufacturers. Since the resulting
10 purified protein was observed to have a small amount of impurity protein according to SDS-PAGE analysis, it was further purified as described below. Protein solution was concentrated to approximately 1 ml using Centriprep 10 (Amicon), dialyzed with water and freeze-dried. After
15 treating with SDS, the impurity protein was separated using Biophoresis (Atoh, 4.5% concentration gel, 10% separation gel, 15 mA, 0.8 ml fractions). Simultaneously with concentration using Ultra-Free 10 (Millipore), the final purified preparation was transferred to PBS buffer
20 (prepared by dissolving 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na₂HPO₄ and 0.24 g of KH₂PO₄ in 1 liter and adjusting the pH to 7.4 with hydrochloric acid) containing 0.1% CHAPS. The protein concentration in the finally purified preparation was 1.0 mg/ml.

25 Example 15. Preparation of SYP8 Antibody Column

Two rabbits were immunized four times with 0.2 mg each of SYP8 antigen (1.0 mg/ml) prepared in Example 14. The initial immunization was performed using Freund's complete adjuvant. Additional immunizations were
30 performed using Freund's incomplete adjuvant. The additional immunizations were performed on days 14, 42 and 56 after the initial immunization. The method was in accordance with Vol. 12 of the Shin Seikagaku Jikken Koza. Blood samples were collected on days 52, 66 and 70
35 after the initial immunization, and after holding the resulting blood for 30 minutes at 37°C, it was allowed to stand undisturbed overnight at 4°C. The clot was removed

to obtain antiserum. After diluting the antiserum two-fold with 0.85% NaCl, one half volume of chilled Freegen (Hoechst Japan) was added and after stirring vigorously, the mixture was centrifuged for 5 minutes at 1500 rpm to remove fat, after which the resulting supernatant was used as antiserum.

The defatted anti-SYP8 antiserum (approx. 45 ml) was diluted with an equal volume of 0.15 M NaCl solution, followed by the addition of ammonium sulfate to 33% saturation and centrifuging for 30 minutes at 8000 rpm. The precipitate was dialyzed with buffer A (0.05M Tris-HCl, pH 8.6, 0.15 M NaCl). The dialysate was applied to a Hi Trap Protein A column (1 ml) to purify an IgG fraction. Namely, the dialyzed sample was applied onto the Hi Trap Protein A column equilibrated with buffer A, and after washing the column with buffer A, the dialyzed sample was sequentially eluted using buffer B (0.05 M citrate buffer, pH 5.3, 0.15 M NaCl), buffer C (0.05 M acetate buffer, pH 4.3, 0.15 M NaCl) and buffer D (0.05 M glycine buffer, pH 2.3, 0.15 M NaCl). IgG was confirmed to be present in both the buffer C and buffer D fractions according to ultraviolet absorption and immunodot blotting, and these fractions were mixed to form an IgG fraction. The amount of protein of the fraction was approximately 70 mg. The resulting IgG fraction was dialyzed with 0.1 M NaHCO₃ and 0.5 M NaCl, after which it was concentrated to approximately 2 mg/ml with Centricon 10 (Amicon).

4.5 g of CNBr-activated Sepharose 4B was suspended in 45 ml of 1 mM HCl and washed with 500 ml of 1 mM HCl over a Buchner funnel. The washed resin was added a little at a time to the concentrated IgG solution and suspended, and shaken overnight at 4°C to immobilize the IgG. The resin was collected by filtration with aspiration over a Buchner funnel, resuspended in 30 ml of 0.2 M Tris-HCl buffer (pH 8.5), and the suspension was shaken for two nights at 4°C so as to inactivate residual

active groups on the resin. Next, the resin was sequentially washed with 0.2 M acetate buffer (pH 5.0), Tris-HCl buffer (pH 8.5), 0.01 M potassium phosphate buffer (pH 7.8) and 0.2 M NaCl. As a control, anti-band A IgG and anti- β -galactosidase IgG were respectively immobilized to Sepharose 4B in the same manner. This Sepharose 4B was used as IgG-Sepharose 4B suspension (anti-SYP8, anti-band A, anti- β -galactosidase) in Example 16. Furthermore, the weight of reacted IgG per unit resin weight was set to be roughly the same for all three types. The immobilization yield was 90 to 100%.

Example 16. Immunoprecipitation Experiment

0, 200, 500 and 815 μ l each of aqueous bovine serum albumin solution (final concentration 0.1%) and IgG-Sepharose 4B suspension prepared in Example 15 (anti-SYP8, anti-band A, anti- β -galactosidase; resin phase:liquid phase = 2:1 v/v) were added to a amount of enzyme solution, and then the mixture was brought to a final volume of 1 ml with 0.01 M potassium phosphate buffer (pH 7.8) and 0.2 M NaCl. After shaking the mixture for 24 hours at 4°C and centrifuging for 20 minutes at 13,000 rpm, aurone synthase activity of the supernatant was measured.

Namely, aurone synthase activity was measured by adding CHAPS having a final concentration of 0.1%, 5 mM H₂O₂ and 0.1 M citrate buffer to the supernatant to make the pH 5.4, bringing the total volume to 395 μ l and holding for 15 minutes at 30°C, followed by addition of 5 μ l of THC (dissolved with ethanol so that A366 = 600) to start the reaction. After allowing to react for 60 minutes at 30°C, 100 μ l of 10% TFA and 90% acetonitrile were added to stop the reaction. Activity was then measured by analyzing the reaction mixture by HPLC as described in Example 3.

As shown in Fig. 6, when anti-SYP8-IgG-Sepharose 4B

was used, enzyme activity in the supernatant decreased dependent on the amount of anti-SYP8-IgG-Sepharose 4B added. There was no change in aurone synthase activity in the case of adding anti-band A-IgG-Sepharose 4B or
5 anti- β -galactosidase-IgG-Sepharose 4B as a control. In addition, the resin collected as precipitate was washed with 0.01 M potassium phosphate buffer and 0.2 M NaCl, followed by measurement of aurone synthase activity. As a result, aurone synthase activity was observed only for
10 anti-SYP8-IgG-Sepharose 4B.

When the supernatant was analyzed by SDS-PAGE and Western blotting, the signal of aurone synthase decreased dependent on the amount of anti-SYP8-IgG-Sepharose 4B as shown in Fig. 7. On the other hand, in a similar
15 experiment using anti-band A-IgG-Sepharose 4B as control, the signal of the aurone synthase gene was constant regardless of the amount of anti-band A-IgG-Sepharose 4B added.

According to these results, SYP8 gene was confirmed to encode aurone synthase. Note that an approximately 80
20 kDa signal was detected dependent on the amount of anti-SYP8-IgG-Sepharose 4B added in Fig. 7. Since this signal increases with storage time of the resin until the experiment, this signal is thought to have been derived
25 from IgG liberated from the Sepharose 4B resin.

Example 17.

As was described in Example 10, aurone synthase demonstrates weak homology with polyphenol oxidase at the amino acid level, and the major region possessing that
30 homology is the region that binds to copper. Accordingly, since it is expected that aurone synthase is also a copper enzyme, atomic absorption analysis was performed on aureusidin synthase. The Shimazu AA-6700F was used for the measurement system, and measurement was
35 performed in the furnace measurement mode at a wavelength of 324.8 nm.

A calibration curve (calibration range: 0 to 9 ppb)

was prepared using a 1000 ppm copper standard solution (Wako Pure Chemical Industries) diluted 1000-fold with concentrated sulfuric acid. Since other organic substances present may obstruct measurement in the case of analysis by atomic absorption analysis, measurement of the atomic absorption of copper was confirmed to be possible even in acetic acid buffer containing 0.1% CHAPS in advance by using mushroom tyrosinase (enzyme containing copper ion) prior to measurement. Next, pure aureusidin synthase (200 μ l) was thoroughly dialyzed against acetic acid buffer (pH 6.0) containing 0.1% CHAPS. Known amounts of several standard proteins were analyzed by SDS-PAGE, the darkness of the resulting silver-colored bands was quantified with an image scanner, and a calibration curve was prepared for determining the amount of protein from band darkness. A portion of the pure aureusidin synthase was applied to SDS-PAGE under the same conditions, its silver-colored band was quantified with an image scanner, and protein concentration was calculated from the previously prepared calibration curve. Copper was detected by adding 0.5 μ l of concentrated sulfuric acid (1.38 N) to 100 μ l of pure aureusidin synthase and measuring. Accordingly, this enzyme was clearly shown to be a copper enzyme.

Example 18. Aurone Synthesis Activity of Tyrosinase

After mixing tyrosinase (Sigma catalog no. T7755; 0.04 mg/ml, 10 μ l), 0.1 M sodium phosphate buffer (pH 6.5, 335 μ l), 9% CHAPS (20 μ l) and milli-Q water (20 μ l), the mixture was incubated for 10 minutes at 30°C, followed by the addition of tetrahydroxychalcone (THC, 4.3 mM in ethanol, 15 μ l), stirring immediately and reacting for 30 minutes at 30°C. After reaction, 100 μ l of reaction stopping solution (10% trifluoroacetate solution containing 90% acetonitrile) was added to the reaction mixture to stop the reaction, followed by HPLC

analysis. Analysis was performed in the same manner as described in Example 3. Water was used instead of tyrosinase as a control.

5 In the case of addition of tyrosinase, the substrate THC was eluted in approximately 15.9 minutes, while the reaction product aureusidin was eluted in approximately 12.5 minutes. On the other hand, in the case of addition of water instead of tyrosinase, the substrate THC was eluted in approximately 16 minutes, while aureusidin was
10 not eluted.

In addition, the reaction was carried out under the same conditions using pentahydroxychalcone (PHC) instead of THC as a substrate, and using 0.116 M sodium citrate phosphate buffer (pH 5.4) as a buffer. Similarly, water
15 was used instead of tyrosinase as a control.

In the case of addition of tyrosinase, the substrate PHC was eluted in approximately 14.7 minutes, while the reaction product aureusidin was eluted in approximately 12.5 minutes. On the other hand, in the case of adding
20 water instead of tyrosinase, although the substrate PHC was eluted in approximately 14.6 minutes, aureusidin was not eluted.

Thus, tyrosinase was clearly shown to also have activity to synthesize aurone.

25 Industrial Applicability

As has been described above, according to the present invention, a reaction in which aureusidin, a kind of aurone, is synthesized from tetrahydroxychalcone was
30 observed for the first time, aureusidin synthase that catalyzes this reaction was isolated and purified, its amino acid sequence was determined, and its gene was cloned. Here, although snapdragon was used for the enzyme source, enzymes that synthesize aurones can be
35 purified from other plants containing aurones using a similar method, and their genes can be obtained.

Alternatively, since genes encoding enzymes that

catalyze the same reaction are known to have mutually homologous nucleotide sequences and hybridize, a gene encoding an enzyme that synthesizes aurones can be obtained from another source based on the cDNA obtained
5 from snapdragon.

In addition, a gene that encodes protein having activity to synthesize aurones by using chalcones as substrates can also be obtained from polyphenol oxidase.

The introduction of a target gene into a plant is
10 currently widely known, and the present invention makes it possible to breed yellow flowers from plant species that do not inherently possess yellow flowers. Moreover, it is also possible to change the color tone in plant species having yellow flowers.

CLAIMS

1. A gene encoding a protein having activity to synthesize aurones by using chalcones as substrates.

2. A gene as set forth in claim 1 wherein said
5 protein is a polyphenol oxidase.

3. A gene as set forth in claim 1 or 2, encoding a protein having the amino acid sequence described in SEQ ID No. 2 or an amino acid sequence modified by deletion, substitution and/or addition of one or more amino acids
10 relative to that amino acid sequence, and having activity to synthesize aurones by using chalcones as substrates.

4. A gene as set forth in claim 1 or 2, capable of hybridizing under stringent conditions with a nucleic acid having the nucleotide sequence described in Sequence
15 ID No. 1, and encoding a protein having activity to synthesize aurones by using chalcones as substrates.

5. A gene as set forth in claim 1 or 2 having sequence homology of at least 55% relative to the amino acid sequence described in SEQ ID No. 2, and encoding a
20 protein having activity to synthesize aurones by using chalcones as substrates.

6. A vector comprising a gene as set forth in any one of claims 1 through 5.

7. A host transformed by a vector as set forth in
25 claim 6.

8. A host as set forth in claim 7 wherein said host is a microorganism or animal cell.

9. A host as set forth in claim 7 wherein said host is a plant cell or plant.

10. A protein encoded by a gene as set forth in any
30 one of claims 1 through 5.

11. A protein able to specifically bind with antibody to the protein as set forth in claim 10, and having activity to synthesize aurones by using chalcones
35 as substrates.

12. A process for production of said protein characterized by culturing or growing a host as set forth

in claim 7, and harvesting or purifying from said host a protein having activity to synthesize aurones by using chalcones as substrates.

5 13. A process for harvesting or purifying a protein having activity to synthesize aurones by using chalcones as substrates, characterized by utilizing specific binding with antibody to the protein as set forth in claim 10 or claim 11.

10 14. A process for synthesizing aurone characterized in that a protein as set forth in claim 10 or claim 11 is allowed to act on chalcones.

15 15. A process for synthesizing aurones in a plant characterized by transforming a plant or plant cells with a gene as set forth in any one of claims 1 through 5, expressing said gene, and using the formed protein to synthesize aurones within a plant.

20 16. A plant in which flower color is regulated by introducing a gene as set forth in any one of claims 1 through 5, or its progeny or tissue having the same properties.

17. A plant as set forth in claim 16 in which flower color is regulated to yellow, or its progeny or tissue having the same properties.

ABSTRACT

5 The present invention provides a protein having
aurone synthase activity involved in the color of flowers
such as snapdragons, a gene that encodes it, cDNA in
particular, and its applications. This gene can give
yellow color to the flowers of plants by introducing into
plants deficient in chalcone isomerase and so forth and
expressing.

Fig. 1






Fig. 2




Fig. 3

Leaf Stem Bud Petal

← 3.4kb



← 1.8kb

Fig. 4

petal stage

1 2 3 4 5 6

 $\frac{3}{6}$

Fig.5

yellow
pink
white

← 3.4kb



← 1.8kb

Fig. 6




Fig. 7

Amount of anti-SYP8-Sepharose 4B
added

0 μ | 200 μ | 500 μ | 815 μ |



Aurone Synthase



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Declaration and Power of Attorney For Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者であると（下記の名称が複数の場合）信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

GENE ENCODING A PROTEIN HAVING

AURONE SYNTHESIS ACTIVITY

上記発明の明細書（下記の欄でx印がついていない場合は、本書に添付）は、

the specification of which is attached hereto unless the following box is checked:

☐ 月 日に提出され、米国出願番号または特許協定条約国際出願番号を _____ とし、
(該当する場合) _____ に訂正されました。

☐ was filed on April 16, 1999
as United States Application Number or
PCT International Application Number
PCT/JP99/02045 and was amended on _____
(if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration

(日本語宣言書)

私は、米国法典第35編119条(a)-(d)項又は365条(b)項に基づき下記の、米国外の国の少なくとも一カ国を指定している特許協力条約365(a)項に基づき国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

Prior Foreign Application(s)

外国での先行出願

10-107296(Pat. Appln.) Japan

(Number)
(番号)(Country)
(国名)(Number)
(番号)(Country)
(国名)

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Not Claimed

優先権主張なし

17/April/1998

(Day/Month/Year Filed)
(出願年月日)(Day/Month/Year Filed)
(出願年月日)

私は、第35編米国法典119条(e)項に基づいて下記の米国外の特許出願規定に記載された権利をここに主張いたします。

(Application No.)
(出願番号)(Filing Date)
(出願日)(Application No.)
(出願番号)(Filing Date)
(出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国外の特許出願に記載された権利、又は米国を指定している特許協力条約365条(c)に基づき権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国外の特許出願に開示されていない限り、その先行米国外出願書提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.)
(出願番号)(Filing Date)
(出願日)(Status: Patented, Pending, Abandoned)
(現況: 特許許可済、係属中、放棄済)(Application No.)
(出願番号)(Filing Date)
(出願日)(Status: Patented, Pending, Abandoned)
(現況: 特許許可済、係属中、放棄済)

私は、私自身の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じることに基づき表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の表明を行えば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration (日本語宣言書)

委任状: 私は下記の発明者として、本出願に関する一切の
手続を米特許商標局に対して遂行する弁理士または代理人
として、下記の者を指名いたします。(弁理士、または代理
人の氏名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint
the following attorney(s) and/or agent(s) to prosecute this
application and transact all business in the Patent and Trademark
Office connected therewith (list name and registration number)

William L. Mathis 17,337
Peter H. Smolka 15,913
Robert S. Swecker 19,885
Platon N. Mandros 22,124
Benton S. Duffett, Jr. 22,030
Joseph R. Magnone 24,239
Norman H. Stepno 22,716
Ronald L. Grudziecki 24,970
Frederick G. Michaud, Jr. 26,003
Alan E. Kopecki 25,813
Regis E. Slutter 26,999
Samuel C. Miller, III 27,360
Ralph L. Freeland, Jr. 16,110

Robert G. Mukai 28,531
George A. Hovanec, Jr. 28,223
James A. LaBarre 28,632
E. Joseph Gess 28,510
R. Danny Huntington 27,903
Eric H. Weisblatt 30,505
James W. Peterson 26,057
Teresa Stanek Rea 30,427
Robert E. Krebs 25,885
William C. Rowland 30,888
T. Gene Dillahunt 25,423
Patrick C. Keane 32,858
Bruce J. Boggs, Jr. 32,344

William H. Benz 25,952
Peter K. Skiff 31,917
Richard J. McGrath 29,195
Matthew L. Schneider 32,814
Michael G. Savage 32,596
Gerald F. Swiss 30,113
Michael J. Ure 33,089
Charles F. Wieland III 33,096
Bruce T. Wieder 33,815
Todd R. Walters 34,040

書類送付先

Send Correspondence to:

Ronald L. Grudziecki
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404

直接電話連絡先: (名前及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Ronald L. Grudziecki
at (703) 836-6620

唯一または第一発明者名	1-00	Full name of sole or first inventor	<u>Keiko Sakakibara</u>
発明者の署名	日付	Inventor's signature	<u>神原 圭子</u> Date <u>Dec. 2, 1999</u>
住所		Residence	<u>Muko-shi, Kyoto, Japan</u> JPX
国籍		Citizenship	<u>Japanese</u>
私書箱		Post Office Address	<u>3-1-327, Nishitanakase, Terado-cho,</u> <u>Muko-shi, Kyoto 617-0002, Japan</u>
第二共同発明者	2-00	Full name of second joint inventor, if any	<u>Yuko Fukui</u>
第二共同発明者	日付	Second inventor's signature	<u>福井 祐子</u> Date <u>Dec. 2, 1999</u>
住所		Residence	<u>Mishima-gun, Osaka, Japan</u> JPX
国籍		Citizenship	<u>Japanese</u>
私書箱		Post Office Address	<u>2-8-2-907, Minase, Shimamoto-cho,</u> <u>Mishima-gun, Osaka 618-0014, Japan</u>

(第三以降の共同発明者についても同様に記載し、署名をす
ること)

(Supply similar information and signature for third and subsequent
joint inventors.)

YF
see paper
No. 6
81

第三共同発明者	3-00	Full name of third joint inventor, if any <u>Yoshikazu Tanaka</u>	
第三共同発明者	日付	Third inventor's signature <u>田中 良和</u>	Date Dec. 2, 1999
住 所		Residence <u>Otsu-shi, Shiga, Japan</u>	<u>JPx</u>
国 籍		Citizenship Japanese	
私書箱		Post Office Address 2-7-4, Oginosato, Otsu-shi, Shiga 520-0246,	
		Japan	
第四共同発明者	4-00	Full name of fourth joint inventor, if any <u>Takaaki Kusumi</u>	
第四共同発明者	日付	Fourth inventor's signature <u>久住高章</u>	Date Dec. 2, 1999
住 所		Residence <u>Suita-shi, Osaka, Japan</u>	<u>JPx</u>
国 籍		Citizenship Japanese	
私書箱		Post Office Address 2-12-21-402, Yamate-cho, Suita-shi,	
		Osaka 564-0073, Japan	

第五共同発明者	5-00	Full name of fifth joint inventor, if any <u>Masako Mizutani</u>	
第五共同発明者	日付	Fifth inventor's signature <u>水谷正子</u>	Date Dec. 2, 1999
住 所		Residence <u>Kyoto-shi, Kyoto, Japan</u>	<u>JPx</u>
国 籍		Citizenship Japanese	
私書箱		Post Office Address 53-60, Katsurainui-cho, Nishikyo-ku, Kyoto-shi, Kyoto 615-8086, Japan	
第六共同発明者	6-00	Full name of sixth joint inventor, if any <u>Toru Nakayama</u>	
第六共同発明者	日付	Sixth inventor's signature <u>中山 亨</u>	Date Dec. 2, 1999
住 所		Residence <u>Sendai-shi, Miyagi, Japan</u>	<u>JPx</u>
国 籍		Citizenship Japanese	
私書箱		Post Office Address 2-1-305, Kitatakamori, Izumi-ku, Sendai-shi, Miyagi 981-3202, Japan	

(第七以降の共同発明者についても同様に
記載し、署名をすること)

(Supply similar information and signature for
seventh and subsequent joint inventors.)

420 Rec'd PCT/PTO 17 DEC 1999

SEQUENCE LISTING

<110> SUNTORY LIMITED

<120> Gene encoding a protein having aurone synthesis activity

<130> G837

<150> JP 10-107296

<151> 1998-04-17

<160> 15

<210> 1

<211> 1951

<212> DNA

<213> Antirrhinum majus

<220>

<221> CDS

<222> (96)...(1781)

<223> Nucleotide sequence encoding a protein having aurone synthesis activity

<400> 1

```

aaattacatt gcttcctttg tccaccttc caccaccaat atatacaact tcttcagcta    60
gttggtttatt atcaatcaaa taaaattatt tccca atg ttc aaa aat cct aat    113
                               Met Phe Lys Asn Pro Asn
                               1           5
atc cgc tat cac aaa cta tct tcc aaa tcc aat gac aac gat caa gaa    161
Ile Arg Tyr His Lys Leu Ser Ser Lys Ser Asn Asp Asn Asp Gln Glu
          10           15           20
tcc tcc cat cgt tgt aag cac att cta tta ttt ata ata acc tta ttc    209
Ser Ser His Arg Cys Lys His Ile Leu Leu Phe Ile Ile Thr Leu Phe
          25           30           35

```

cta ctt ata gtt ggc ctg tac atc gcc aac tct ctc gcc tat gcc cgg	257
Leu Leu Ile Val Gly Leu Tyr Ile Ala Asn Ser Leu Ala Tyr Ala Arg	
40 45 50	
ttt gcc tog acc tca acc ggc cct atc gcc gcc cct gat gtc acc aaa	305
Phe Ala Ser Thr Ser Thr Gly Pro Ile Ala Ala Pro Asp Val Thr Lys	
55 60 65 70	
tgt ggt cag cca gac ttg cca cct ggc aca gcc cca ata aac tgt tgt	353
Cys Gly Gln Pro Asp Leu Pro Pro Gly Thr Ala Pro Ile Asn Cys Cys	
75 80 85	
ccc cca atc ccc gct aaa atc atc gat ttc gag cta cca cct ccc tcc	401
Pro Pro Ile Pro Ala Lys Ile Ile Asp Phe Glu Leu Pro Pro Pro Ser	
90 95 100	
act acc atg agg gtt cgc cgt gcg gct cat tta gtt gat gat gca tac	449
Thr Thr Met Arg Val Arg Arg Ala Ala His Leu Val Asp Asp Ala Tyr	
105 110 115	
att gcc aaa ttc aag aaa gcc gtt gag ctt atg cga gct cta cct gag	497
Ile Ala Lys Phe Lys Lys Ala Val Glu Leu Met Arg Ala Leu Pro Glu	
120 125 130	
gat gac cct cgt agc ttc aag caa caa gct aac gtc cat tgc gct tac	545
Asp Asp Pro Arg Ser Phe Lys Gln Gln Ala Asn Val His Cys Ala Tyr	
135 140 145 150	
tgc gcg ggg gcg tat aat caa gcc ggt ttc aca aac cta aag ctc caa	593
Cys Ala Gly Ala Tyr Asn Gln Ala Gly Phe Thr Asn Leu Lys Leu Gln	
155 160 165	
atc cac cga tct tgg ctt ttt ttc ccg ttc cat aga tat tat atc tac	641
Ile His Arg Ser Trp Leu Phe Phe Pro Phe His Arg Tyr Tyr Ile Tyr	
170 175 180	
ttt ttt gaa aga ata ttg gga aaa cta atc aat gat aca act ttt gct	689
Phe Phe Glu Arg Ile Leu Gly Lys Leu Ile Asn Asp Thr Thr Phe Ala	
185 190 195	
ctc cca ttt tgg aac tat gat tca cct ggt gga atg aca atc cca tca	737
Leu Pro Phe Trp Asn Tyr Asp Ser Pro Gly Gly Met Thr Ile Pro Ser	
200 205 210	
atg ttt att gat act aat tct tcg ctg tac gat agt tta cgg gac agt	785
Met Phe Ile Asp Thr Asn Ser Ser Leu Tyr Asp Ser Leu Arg Asp Ser	
215 220 225 230	
aat cat cag cca cca acc atc gta gac ttg aac tac gcc ttt tct gat	833
Asn His Gln Pro Pro Thr Ile Val Asp Leu Asn Tyr Ala Phe Ser Asp	
235 240 245	

tcc gac aat acc act act cct gaa gag caa atg att ata aac ctt aaa	881
Ser Asp Asn Thr Thr Thr Pro Glu Glu Gln Met Ile Ile Asn Leu Lys	
250 255 260	
att gtg tac aga caa atg gtg tcg agc gct aag act cca cag ctt ttc	929
Ile Val Tyr Arg Gln Met Val Ser Ser Ala Lys Thr Pro Gln Leu Phe	
265 270 275	
ttc ggc cgc cca tac cga cgt ggg gac caa gag ttt ccc ggg gtg ggg	977
Phe Gly Arg Pro Tyr Arg Arg Gly Asp Gln Glu Phe Pro Gly Val Gly	
280 285 290	
tcg att gag tta gtc cct cat ggc atg ata cat tta tgg acc ggt tct	1025
Ser Ile Glu Leu Val Pro His Gly Met Ile His Leu Trp Thr Gly Ser	
295 300 305 310	
gag aac acg ccc tat ggc gag aac atg ggg gct ttc tac tca acg gct	1073
Glu Asn Thr Pro Tyr Gly Glu Asn Met Gly Ala Phe Tyr Ser Thr Ala	
315 320 325	
aga gac ccg ata ttt ttt gct cat cat tcg aac gtc gat aga atg tgg	1121
Arg Asp Pro Ile Phe Phe Ala His His Ser Asn Val Asp Arg Met Trp	
330 335 340	
tcc ata tgg aag acc cta gga ggg ccg cgg agg acg gac tta aca gat	1169
Ser Ile Trp Lys Thr Leu Gly Gly Pro Arg Arg Thr Asp Leu Thr Asp	
345 350 355	
cca gat ttt ctt gat gcg tct ttc gtt ttt tat gac gaa aac gca gag	1217
Pro Asp Phe Leu Asp Ala Ser Phe Val Phe Tyr Asp Glu Asn Ala Glu	
360 365 370	
atg gtt cgg gtc aag gtt cgg gat tgc tta gat gaa aag aaa cta ggg	1265
Met Val Arg Val Lys Val Arg Asp Cys Leu Asp Glu Lys Lys Leu Gly	
375 380 385 390	
tac gtt tat caa gat gtg gag att ccg tgg ctc aac act cgt cca aca	1313
Tyr Val Tyr Gln Asp Val Glu Ile Pro Trp Leu Asn Thr Arg Pro Thr	
395 400 405	
cca aaa gtt tct ccg tct cta ctt aag aaa ttt cat aga aca aac act	1361
Pro Lys Val Ser Pro Ser Leu Leu Lys Lys Phe His Arg Thr Asn Thr	
410 415 420	
gcc aat ccg aga caa gtt ttt cct gcg ata ctt gac aga gtc tta aaa	1409
Ala Asn Pro Arg Gln Val Phe Pro Ala Ile Leu Asp Arg Val Leu Lys	
425 430 435	
gtt atc gtg acg agg ccg aag aaa act aga agt agg aaa gaa aag gac	1457
Val Ile Val Thr Arg Pro Lys Lys Thr Arg Ser Arg Lys Glu Lys Asp	
440 445 450	

gag tta gaa gag att tta gtg att gaa ggg att gaa ctg gaa aga gac 1505
 Glu Leu Glu Glu Ile Leu Val Ile Glu Gly Ile Glu Leu Glu Arg Asp
 455 460 465 470
 cac ggg cac gta aaa ttc gac gtt tat att aat gct gac gaa gat gac 1553
 His Gly His Val Lys Phe Asp Val Tyr Ile Asn Ala Asp Glu Asp Asp
 475 480 485
 ctt gcg gtg att tcg ccg gag aat gct gag ttc gcc ggg agt ttc gtg 1601
 Leu Ala Val Ile Ser Pro Glu Asn Ala Glu Phe Ala Gly Ser Phe Val
 490 495 500
 agt ctg tgg cac aaa cct ata aag ggg aag agg aca aag acg cag tta 1649
 Ser Leu Trp His Lys Pro Ile Lys Gly Lys Arg Thr Lys Thr Gln Leu
 505 510 515
 tta aca ttg tcg att tgt gat att ttg gag gat ttg gat gct gac gaa 1697
 Leu Thr Leu Ser Ile Cys Asp Ile Leu Glu Asp Leu Asp Ala Asp Glu
 520 525 530
 gat gat tat gtg ttg gtc act ttg gtt ccg aga aac gcc gga gat gcg 1745
 Asp Asp Tyr Val Leu Val Thr Leu Val Pro Arg Asn Ala Gly Asp Ala
 535 540 545 550
 atc aag att cat aat gtc aag att gag ott gat ggc taataaatc 1791
 Ile Lys Ile His Asn Val Lys Ile Glu Leu Asp Gly
 555 560 562
 tattgatttc ttctcaacct acagttgatc atttaccgat tgattattcc aataaaagta 1851
 tctcatgtac caatatcgat cgtattaatc gtaatacttt cagattttta tttatttaaa 1911
 agcagttgta taaatggtga aataaggatt acttttttgag 1951

<210> 2

<211> 562

<212> PRT

<213> Antirrhinum majus

<220>

<223> Amino acid sequence of a protein having aurone synthesis activity

<400> 2

Met Phe Lys Asn Pro Asn Ile Arg Tyr His Lys Leu Ser Ser Lys Ser
 1 5 10 15

Asn Asp Asn Asp Gln Glu Ser Ser His Arg Cys Lys His Ile Leu Leu
 20 25 30
 Phe Ile Ile Thr Leu Phe Leu Leu Ile Val Gly Leu Tyr Ile Ala Asn
 35 40 45
 Ser Leu Ala Tyr Ala Arg Phe Ala Ser Thr Ser Thr Gly Pro Ile Ala
 50 55 60
 Ala Pro Asp Val Thr Lys Cys Gly Gln Pro Asp Leu Pro Pro Gly Thr
 65 70 75 80
 Ala Pro Ile Asn Cys Cys Pro Pro Ile Pro Ala Lys Ile Ile Asp Phe
 85 90 95
 Glu Leu Pro Pro Pro Ser Thr Thr Met Arg Val Arg Arg Ala Ala His
 100 105 110
 Leu Val Asp Asp Ala Tyr Ile Ala Lys Phe Lys Lys Ala Val Glu Leu
 115 120 125
 Met Arg Ala Leu Pro Glu Asp Asp Pro Arg Ser Phe Lys Gln Gln Ala
 130 135 140
 Asn Val His Cys Ala Tyr Cys Ala Gly Ala Tyr Asn Gln Ala Gly Phe
 145 150 155 160
 Thr Asn Leu Lys Leu Gln Ile His Arg Ser Trp Leu Phe Phe Pro Phe
 165 170 175
 His Arg Tyr Tyr Ile Tyr Phe Phe Glu Arg Ile Leu Gly Lys Leu Ile
 180 185 190
 Asn Asp Thr Thr Phe Ala Leu Pro Phe Trp Asn Tyr Asp Ser Pro Gly
 195 200 205
 Gly Met Thr Ile Pro Ser Met Phe Ile Asp Thr Asn Ser Ser Leu Tyr
 210 215 220
 Asp Ser Leu Arg Asp Ser Asn His Gln Pro Pro Thr Ile Val Asp Leu
 225 230 235 240
 Asn Tyr Ala Phe Ser Asp Ser Asp Asn Thr Thr Thr Pro Glu Glu Gln
 245 250 255
 Met Ile Ile Asn Leu Lys Ile Val Tyr Arg Gln Met Val Ser Ser Ala
 260 265 270
 Lys Thr Pro Gln Leu Phe Phe Gly Arg Pro Tyr Arg Arg Gly Asp Gln
 275 280 285
 Glu Phe Pro Gly Val Gly Ser Ile Glu Leu Val Pro His Gly Met Ile
 290 295 300
 His Leu Trp Thr Gly Ser Glu Asn Thr Pro Tyr Gly Glu Asn Met Gly
 305 310 315 320

<223> Partial amino acid sequence of a protein having
aurone synthesis activity

<400> 3

Lys Lys Leu Gly Tyr Val Tyr Gln Asp Val Glu Ile Pro
5 10

<210> 4

<211> 12

<212> PRT

<213> Antirrhinum majus

<220>

<223> Partial amino acid sequence of a protein having
aurone synthesis activity

<400> 4

Lys Ile Val Tyr Arg Gln Met Val Ser Ser Ala Lys
5 10

<210> 5

<211> 18

<212> PRT

<213> Antirrhinum majus

<220>

<223> Partial amino acid sequence of a protein having
aurone synthesis activity

<400> 5

Lys Thr Pro Gln Leu Phe Phe Gly Arg Pro Tyr Arg Arg Gly Asp Gln
5 10 15
Glu Phe

<210> 6

<211> 30

<212> PRT

[illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible][illegible]

Lys	Thr	Leu	Gly	Gly	Pro	Arg	Arg	Thr	Asp	Leu	Thr	Asp	Pro	Asp	Phe
				85					90					95	
Leu	Asp	Ala	Ser	Phe	Val	Phe	Cys	Asp	Glu	Asn	Ala	Glu	Met	Val	Arg
		100						105					110		
Val	Lys	Val	Arg	Asp	Cys	Leu	Asp	Gly	Lys	Lys	Leu	Gly			
		115					120					125			

<210> 8
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <221>
 <222> (2)
 <223> Xaa is Val or Ile

<400> 8
 Phe Xaa Lys Phe Thr Ala Ile
 5

<210> 9
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <221>
 <222> (6)
 <223> Xaa is Thr or Pro

<400> 9
 Lys Trp Lys Gly Lys Xaa
 5

<210> 10
 <211> 6

<212> PRT

<213> Artificial Sequence

<220>

<221>

<222>

<223>

<400> 10

His Ala Val Cys Asn Glu

5

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<221>

<222>

<223> Primer

<400> 11

ttyrtnaart tyacngcnat

20

<210> 12

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<221>

<222>

<223> Primer

<400> 12

aartggaarg gnaarmc

17

<210> 13
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<221>
<222>
<223> Primer

<400> 13
rtgngcnacr carttytc

18

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221>
<222>
<223> Primer

<400> 14
aaggatccgg ccctatcgcc

20

<210> 15
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<221>
<222>
<223> Primer

<400> 15

gggttogaag aattcatctc tg

22